Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

´ëÀå»ù¾ÏÁ¾¿¡¼­¿¹ÈÄÀÎÀڷμ­ÀÇFascin, MMP-9 °ú¹ßÇö°ú Proliferating Index¿¡ ´ëÇÑ ¸é¿ªÁ¶Á÷ È­ÇÐÀû ¿¬±¸ Immunohistochemical Studies of Fascin, MMP-9 Overexpression, and Proliferating Index as Prognostic Factors in Cases of a Colon Adenocarcinoma

´ëÇÑ´ëÀåÇ×¹®ÇÐȸÁö 2009³â 25±Ç 6È£ p.393 ~ 400
±è¹ü±Ô, ÇÏ°æ¿ø, ¹ÚÁؼ®, À¯ÀçÇü,
¼Ò¼Ó »ó¼¼Á¤º¸
±è¹ü±Ô ( Kim Beom-Gyu ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

ÇÏ°æ¿ø ( Ha Kyung-Won ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
¹ÚÁؼ® ( Park Jun-Seok ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
À¯ÀçÇü ( Yoo Jae-Hyung ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Abstract


Purpose: The malignant conversion of epithelial cells involves alterations in the expression and the function of cell-matrix and cell-cell adhesive systems that enable a switch to a migratory phenotype in tumor invasion and metastasis. Here, the author studies the prevalence and the potential clinical significance of fascin and Matrix metalloproteinase-9 (MMP-9) expression in relation to the progression of colon adenocarcinoma and of tumor cell proliferation as measured by using the topoisomerase II-¥á(Topo II-¥á) index.

Methods: Relatively well-preserved paraffin-embedded tissues of 120 cases of colon adenocarcinomas were immunohistochemically stained for fascin, MMP-9, and Topo II-¥áexpression. A reaction was determined as being positive when more than 10% of the cells were positive for fascin, and/or MMP-9. The Topo II-¥áindex is defined as the positive number of tumor cells divided by the total number of tumor cells counted times 100. At least 1,000 cells were counted for this analysis. A ¥ö2 test, by using Epi info 2000, for Fascin and/or MMP-9 and a two-sided test for the Topo II-¥áindex were employed with a significance of P<0.05.

Results: Positive reactions for fascin and MMP-9 in colon adenocarcinomas were 44.2% and 56.7%, respectively. In clinically annotated tumors, fascin immunoreactivity was more common in tumors located in the right colon (P=0.014) and was associated with older age (>65 yr, P=0.028), tumor grading (P=0.009), and lymph node metastases (P=0.005). However, MMP-9 immunoreactivity was not statistically associated with age, gender, tumor stage, or lymph node metastases. Fascin expression was statistically associated with MMP-9 expression, especially for left colon adenocarcinomas (P=0.0032). Although the topo II-¥áproliferating index was associated with lymph node metastasis (P<0.01), this result was not statistically associated with Fascin or MMP-9 expression.

Conclusion: Fascin expression may be closely linked with tumor grading and lymph node metastasis of more aggressive colon adenocarcinomas and partly associated with MMP-9 expression in tumor invasion. However, further studies of fascin expression as an independent prognostic factor are required for the determination of significant relationships with other clinicopathologic indices.

Å°¿öµå

Fascin;MMP-9;Topoisomerase II-¥á;´ëÀå»ù¾ÏÁ¾
Fascin;MMP-9;Topoisomerase II-¥á;Colon adenocarcinoma

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS